Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics Limited has applied for quotation of 240,385 new ordinary fully paid shares on the Australian Securities Exchange. The new securities, issued on May 12, 2026, arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s listed share capital and potentially enhancing liquidity for investors.
The additional share quotation reflects ongoing capital management and may provide Amplia with incremental funding flexibility as it advances its therapeutic programs. While the size of the issuance is relatively small, the move underscores continued investor engagement with the stock and supports the company’s presence in the public markets.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is a biotechnology company listed on the ASX under the code ATX. The company operates in the life sciences sector, focusing on developing therapeutic products, with its shares traded on the Australian securities market.
Average Trading Volume: 4,616,710
Technical Sentiment Signal: Hold
Current Market Cap: A$66.7M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.